In RML-infected mice receiving Trazodone HCl, some treated animals developed neurologically definite clinical prion disease. In APP/PS1 mice, oral Trazodone treatment resulted in differential gene expression in the cerebral cortices. In prion model mice, Trazodone HCl significantly rescued hippocampal synapse density compared with prion-only animals, although not to wild-type levels. In tau model mice, Trazodone HCl reduced p-tau levels, whereas DBM did not. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Clinical prion disease in infected mice
Animal study · RML-infected tg37+/− mice [1]
RML-infected tg37+/− mice received Trazodone HCl intraperitoneally once daily, with vehicle-treated animals as controls. Some trazodone-treated mice developed neurologically definite clinical prion disease.
Conditions shared by the study groups
- Route
- intraperitoneally
- Treatment course
- once daily; from 7 weeks post-infection until terminal clinical sign appeared
- Vehicle
- sterile saline
- Trazodone HCl 40 mg/kg
- Model: RML-infected tg37+/− mice
Methods and source locations
Compound reported in the paper: Trazodone HCl; Compound label in the paper: Trazodone
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Prion infection of mice (S54); Materials and methods > Pharmacological treatment of mice (S57, S58); Results > Trazodone and dibenzoylmethane prevent neurological signs of prion disease in prion-infected mice (S154, S157); Table 1 legend (S254, S255)
neurologically definite clinical prion disease: neurologically definite clinical prion disease; comparator: vehicle-treated animals (n = 20) — Materials and methods > Pharmacological treatment of mice (S57); Table 1 legend (S255)
Trazodone HCl 40 mg/kg · Materials and methods > Pharmacological treatment of mice (S57, S58); Table 1 legend (S255)
Cortical gene expression in amyloid model mice
Animal study · APP/PS1 mice [2]
APP/PS1 mice received Trazodone by oral gavage. Compared with untreated controls, treatment resulted in differential gene expression in the cerebral cortices, with 842 genes upregulated and 503 downregulated.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- 14 consecutive days
- Trazodone 10 mg/kg body weight per day
- Model: APP/PS1 mice
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Trazodone
The paper names Trazodone without stating the salt or form; not verified as the hydrochloride form supplied as A11703. No dose conversion or lot validation.
Results > Trazodone Treatment Downregulates sST2 and Ameliorates Amyloid Pathology in APP/PS1 Transgenic Mice. (S8); Results > Trazodone Treatment Restores the Expression of Synaptic Genes in APP/PS1 Transgenic mice. (S28); Materials and Methods > In Vivo Administration of Trazodone in Mice and Tissue Collection. (S62); Fig. 3. legend (S107)
differentially expressed genes (DEGs) in the cerebral cortices: differentially expressed genes (DEGs) in the cerebral cortices; comparator: untreated control (CTRL) — Results > Trazodone Treatment Downregulates sST2 and Ameliorates Amyloid Pathology in APP/PS1 Transgenic Mice. (S8); Results > Trazodone Treatment Restores the Expression of Synaptic Genes in APP/PS1 Transgenic mice. (S28); Fig. 3. legend (S107)
Trazodone 10 mg/kg body weight per day · Results > Trazodone Treatment Downregulates sST2 and Ameliorates Amyloid Pathology in APP/PS1 Transgenic Mice. (S8); Results > Trazodone Treatment Restores the Expression of Synaptic Genes in APP/PS1 Transgenic mice. (S28); Materials and Methods > In Vivo Administration of Trazodone in Mice and Tissue Collection. (S62)
Hippocampal Synapse Density Following Treatment
Animal study · Prion tg37+/− mice [3]
Prion tg37+/− mice received Trazodone HCl intraperitoneally. Compared with prion-only animals, treatment significantly rescued hippocampal synapse density, although not to wild-type levels.
Conditions shared by the study groups
- Route
- intraperitoneally
- Treatment course
- once daily; from 8 to 10 weeks post-inoculation (wpi)
- Vehicle
- saline
- Trazodone HCl 40 mg/kg
- Model: Prion tg37+/− mice
Methods and source locations
Compound reported in the paper: Trazodone HCl; Compound label in the paper: Trazodone
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Prion infection, pharmacological treatment and metabolic labelling (S1, S2); Materials and methods > Electron microscopy (S70); Results > Quantitative and functional rescue of synapses and mitochondria by trazodone (S157); Figure 5 legend (S207)
Synapse number quantification of the hippocampal CA1 neuropil: Synapse number quantification of the hippocampal CA1 neuropil; comparator: prion only and control (NBH) animals — Results > Quantitative and functional rescue of synapses and mitochondria by trazodone (S157); Figure 5 legend (S207)
Trazodone HCl 40 mg/kg · Materials and methods > Prion infection, pharmacological treatment and metabolic labelling (S2); Results > Quantitative and functional rescue of synapses and mitochondria by trazodone (S157)
Phosphorylated tau levels in tau model mice
Animal study · rTg4510 tauP301L+ mice [1]
rTg4510 tauP301L+ mice received Trazodone HCl intraperitoneally once daily. Trazodone, but not DBM, reduced p-tau levels measured by the AT100 antibody.
Conditions shared by the study groups
- Route
- intraperitoneally
- Treatment course
- once daily; from 4 months until 8 months
- Vehicle
- sterile saline
- Trazodone HCl 40 mg/kg
- Model: rTg4510 tauP301L+ mice
Methods and source locations
Compound reported in the paper: Trazodone HCl; Compound label in the paper: Trazodone
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Pharmacological treatment of mice (S57, S58); Results > Trazodone and dibenzoylmethane are neuroprotective in the rTg4510 model of frontotemporal dementia (S199); Figure 4 legend (S239, S244, S245)
p-tau levels measured by the AT100 antibody: p-tau levels measured by the AT100 antibody; comparator: vehicle- or DBM-treated mice — Materials and methods > Pharmacological treatment of mice (S57, S58); Figure 4 legend (S244, S245)
Trazodone HCl 40 mg/kg · Materials and methods > Pharmacological treatment of mice (S57, S58); Figure 4 legend (S245)